PapersPMID:37727187
Early Trends to Show the Efficacy of Cordyceps militaris in Mild to Moderate COVID Inflammation.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 15 days
- Dose studied, every finding
- 500 mg capsule three times daily after meals for 15 days
- Population, every finding
- Adults with mild or moderate COVID-19, all patients pooled; standard-of-care treatment given in both arms
No finding here moved its endpoint.
What did not
How to read these marks →“Also, the comparison of IL-6, ferritin, LDH, CRP, and D-dimer between the patients receiving Cordyceps capsules and placebo capsules was not statistically significant.”
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Patients with mild to moderate COVID-19 at MGM Hospital Navi Mumbai; Cordyceps militaris mycelium capsules (500 mg, adenosine 0.96 mg, cordycepin 4.5 mg) as add-on to standard therapy
- Participants
- 65
- Comparator
- placebo
- Duration
- 15 days
- Endpoints measured
- 108